Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00824265 · ClinicalTrials.gov registry record · Phase 3
Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 365
- Enrollment target
NCT00824265 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 365 participants.
The verdict
NCT00824265, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 365 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).
Interventions
- DRUG OFC Infusion
- DRUG FC infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2009-03-12 |
| Est. Completion | 2017-10-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00824265
The ClinicalTrials.gov registry entry for NCT00824265 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 365 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OFC Infusion is the first listed.
NCT00824265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00824265 about?
NCT00824265 is a clinical study titled "Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia". The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).
What is the current status of trial NCT00824265?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 365 participants. The study started on 2009-03-12. Estimated completion is 2017-10-25.
What interventions are being tested in trial NCT00824265?
The interventions under investigation include: OFC Infusion (DRUG), FC infusion (DRUG).
Who is sponsoring clinical trial NCT00824265?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.